NCT00000746View on ClinicalTrials.gov

A Phase I, Multicenter, Randomized Trial to Evaluate the Safety and Immunogenicity of a Recombinant Vaccinia-HIV Envelope Vaccine (HIVAC-1e) in Combination With a Panel of Subunit Recombinant HIV Envelope Vaccines

PHASE1CompletedINTERVENTIONAL
Enrollment

56

Participants

Timeline

Start Date

Not specified

Study Completion Date

July 31, 1994

Conditions
HIV Infections
Interventions
BIOLOGICAL

rgp120/HIV-1 SF-2

BIOLOGICAL

Env 2-3

BIOLOGICAL

HIVAC-1e

BIOLOGICAL

gp160 Vaccine (MicroGeneSys)

Trial Locations (1)

Unknown

JHU AVEG, Pittsburgh

All Listed Sponsors
lead

National Institute of Allergy and Infectious Diseases (NIAID)

NIH